PE-22-28

PE-22-28 is a synthetic 7-amino-acid peptide corresponding to residues 22 through 28 of the Spadin sequence, which is itself derived from the sortilin propeptide. The compound inhibits TREK-1, a two-pore-domain potassium channel (K2P) involved in neuronal excitability regulation. TREK-1 inhibition has emerged as a target for fast-acting antidepressant pharmacology based on rodent studies showing that TREK-1 knockout mice display antidepressant-resistant phenotypes.

The research lineage runs through the work of Jean Mazella and colleagues at the Institut de Pharmacologie Moléculaire et Cellulaire in Sophia Antipolis, France. The 2010 paper in PLOS Biology identified Spadin as a sortilin-derived peptide with TREK-1 inhibitory activity and antidepressant-like effects in mouse models. Subsequent work characterized shorter active fragments and analogs. PE-22-28 emerged as a stabilized analog with retained TREK-1 inhibitory activity and improved pharmacokinetics compared with the parent Spadin.

The mechanistic argument for TREK-1 inhibition as an antidepressant target rests on several lines of evidence:

• TREK-1 knockout mice show resistance to depression-like phenotypes in chronic stress models
• SSRIs and other established antidepressants increase TREK-1 activity, suggesting compensatory pathways
• Direct TREK-1 inhibition might produce antidepressant effects with faster onset than SSRI receptor-modulation pathways
• TREK-1 is expressed in brain regions involved in mood regulation

This is an active area of preclinical neuropsychopharmacology research. The translation from rodent target identification to human antidepressant approval is historically difficult, with many promising mechanisms failing in Phase 2 and Phase 3 trials due to translation gaps between rodent depression models and human disease.

The Animal Evidence

Rodent forced swim test (FST) and tail suspension test (TST). PE-22-28 administration reduced immobility times in classical screening models for antidepressant activity. The effects were observed within hours of administration, faster than the weeks required for SSRI effects in similar models.

Chronic mild stress models. PE-22-28 reversed anhedonia and other depression-like behavioral changes in mice exposed to chronic mild stress.

Mechanism studies. The Borsotto and colleagues 2015 paper and the Veyssiere and colleagues 2015 paper characterized the TREK-1 inhibition mechanism in cellular and tissue models.

Comparison with SSRIs in rodent models. PE-22-28 produced behavioral effects comparable to or exceeding SSRIs in some rodent paradigms, with faster onset.

The animal dataset is meaningful within the rodent depression-model framework. The well-known limitations of rodent depression models (validity for human depression, predictive value for clinical trial outcomes) apply.

The Human Evidence

There is none.

No registered ClinicalTrials.gov trial exists for PE-22-28 or its parent Spadin. No Phase 1 safety data has been published. The compound has not entered human dose-finding or proof-of-concept testing as of May 2026.

The translation gap from preclinical antidepressant pharmacology to clinical efficacy is a well-documented graveyard of mechanism-based compounds. Whether PE-22-28 would translate the rodent effects to human depression treatment is unknown and remains untested.

Regulatory and Legal Status

FDA. No approval. No IND filing visible in public records as of May 2026.

EMA. No approval.

Compounding. Not on FDA bulk drug substances list.

WADA. Not on 2026 Prohibited List.

Research-chemical availability. Some vendors offer PE-22-28-labeled product. Identity verification is the buyer's responsibility.

The mechanism is TREK-1 potassium channel inhibition.

TREK-1 biology. TREK-1 (encoded by the KCNK2 gene) is a two-pore-domain potassium channel (K2P) expressed in neurons throughout the brain, particularly in regions involved in mood regulation including the prefrontal cortex, hippocampus, and dorsal raphe nucleus. It functions as a background or leak potassium channel that helps set resting membrane potential and modulates neuronal excitability. TREK-1 is activated by mechanical stretch, acidic pH, polyunsaturated fatty acids, and certain anesthetics.

TREK-1 in depression. TREK-1 knockout mice show resistance to depression-like behaviors and to the antidepressant effects of SSRIs, suggesting that TREK-1 is a critical molecular target in mood pathway regulation. The hypothesis is that pharmacological TREK-1 inhibition could produce antidepressant effects directly, without requiring the cascade of receptor and downstream changes initiated by SSRIs.

PE-22-28 inhibition. The peptide binds TREK-1 and inhibits its channel activity. The exact binding site and structural mechanism have been characterized in cellular electrophysiology studies. The inhibition is reversible and dose-dependent.

Downstream consequences. TREK-1 inhibition in serotonergic neurons of the dorsal raphe nucleus would be expected to increase neuronal excitability, with downstream effects on serotonin release in mood-relevant projection regions. This pathway provides a mechanistic rationale for fast-onset antidepressant effects that would not require the multi-week timeline of conventional SSRI receptor-adaptation.

Pharmacokinetics. Specific human PK data is not available. Rodent studies have used intravenous, intraperitoneal, and intranasal administration. The intranasal route is particularly attractive for CNS-active peptides because of nose-to-brain transport bypassing the blood-brain barrier. PE-22-28 includes modifications (compared with parent Spadin) intended to improve protease resistance and brain penetration.

Off-target activity. TREK-1 is expressed in tissues outside CNS, including kidney, gut, and immune cells. The clinical significance of peripheral TREK-1 inhibition at antidepressant doses has not been fully characterized.

Animal-model effects from published preclinical work:

• Reduction in immobility times in forced swim and tail suspension tests
• Reversal of anhedonia and depression-like behaviors in chronic stress models
• Fast onset of behavioral effects (hours rather than weeks)
• Effects comparable to or exceeding SSRIs in some rodent paradigms
• No obvious toxicity at doses tested in published rodent work

Research-chemical user reports describe:

• Subjective mood elevation within hours of intranasal administration
• Reduced anxiety symptoms in some users
• Possible cognitive clarity and focus improvements
• No serious adverse events in informal community use

User reports are anecdotal, uncontrolled, and not verified for vial identity. They constitute the weakest tier of evidence. Subjective mood improvements from research-chemical use are particularly susceptible to placebo effects and expectation bias.

No standardized human dosing protocol exists for PE-22-28 because no human clinical trial has been published.

Rodent studies have used intravenous, intraperitoneal, and intranasal routes at doses scaled to rodent body weight. Translation to human equivalents requires proper pharmacokinetic scaling that has not been performed.

Research-chemical user protocols typically use:

• Intranasal administration at 200 to 500 mcg per day
• Subcutaneous administration at similar daily totals
• Cycle lengths of 2 to 4 weeks with breaks between cycles

These doses are extrapolated from rodent body-surface-area scaling and informal community experience. They are not supported by clinical pharmacokinetic data. The intranasal route has the strongest mechanistic rationale for CNS delivery but lacks human pharmacokinetic characterization for PE-22-28 specifically.

Animal toxicology has not flagged dose-limiting toxicity in the rodent studies published to date. Long-term human safety data does not exist because the compound has not entered human clinical testing.

Theoretical concerns based on mechanism and class:

• Effects on TREK-1 in peripheral tissues (kidney, gut, immune cells) at chronic high doses are unknown
• Drug-drug interactions with SSRIs, SNRIs, MAOIs, atypical antidepressants, and other psychotropic medications have not been studied
• Effects on patients with bipolar disorder (where antidepressant treatment can trigger mania) are unknown
• Effects on seizure threshold are not characterized
• Long-term effects on neural circuit function with chronic TREK-1 inhibition are unstudied

These concerns are mechanistic flags that Phase 1 safety studies would normally address. Those studies have not occurred.

The fast-onset claim itself raises a specific safety question. Slow-onset antidepressants (SSRIs) provide several weeks during which clinical response can be monitored and patient stability can be assessed. Fast-onset antidepressants raise risks of rapid mood shifts, particularly in patients with bipolar diathesis. This consideration applies to ketamine and its derivatives in clinical use; whether it applies to TREK-1 inhibitors has not been formally evaluated.

PE-22-28 has no widely circulated stack combinations in research-chemical communities. The compound is more often used as a standalone investigational antidepressant than in combination protocols.

For broader nootropic stacking, theoretical combinations with Selank, Semax, N-Acetyl Selank Amidate, or Cerebrolysin could be constructed for combined mood and cognitive effects. None of these combinations has been studied in any controlled setting.

For users with diagnosed depression or other mood disorders, the relevant comparators are established treatments with substantial Phase 3 evidence:

• SSRIs (sertraline, escitalopram, fluoxetine, others) — First-line for major depression, decades of trial data, well-characterized safety profiles
• SNRIs (venlafaxine, duloxetine) — First-line alternatives with similar evidence base
• Atypical antidepressants (bupropion, mirtazapine) — Second-line options with different receptor profiles
• Ketamine and esketamine (Spravato) — Fast-acting, FDA-approved for treatment-resistant depression, with substantial Phase 3 evidence; the closest mechanistic peer to TREK-1 inhibitors in fast-onset positioning
• Psychotherapy (CBT, IPT, others) — Substantial evidence base, often more durable than medication for moderate depression

PE-22-28 has no comparable evidence base and is not a substitute for any of these established treatments in clinically significant mood disorders. Self-treatment of depression with research chemicals carries substantial risk and is strongly inadvisable. Depression is a medically serious condition requiring proper diagnosis and evidence-based treatment.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.